Back to Search
Start Over
Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?
- Source :
-
Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2021 Sep 01; Vol. 78 (3), pp. 331-333. - Publication Year :
- 2021
-
Abstract
- Competing Interests: A. Abbate has served as a consultant for Astra Zeneca, Effetti, Implicit Biosciences, Kiniksa, Janssen, Merck, Novartis, Olatec, and Serpin pharma. The remaining authors report no conflicts of interest.
- Subjects :
- Aminobutyrates adverse effects
Angiotensin II Type 1 Receptor Blockers adverse effects
Animals
Biphenyl Compounds adverse effects
Clinical Decision-Making
Disease Models, Animal
Drug Combinations
Evidence-Based Medicine
Heart Disease Risk Factors
Heart Failure diagnosis
Heart Failure mortality
Humans
Myocardial Infarction diagnosis
Myocardial Infarction mortality
Neprilysin antagonists & inhibitors
Protease Inhibitors adverse effects
Protective Factors
Risk Assessment
Treatment Outcome
Valsartan adverse effects
Aminobutyrates therapeutic use
Angiotensin II Type 1 Receptor Blockers therapeutic use
Biphenyl Compounds therapeutic use
Heart Failure prevention & control
Myocardial Infarction drug therapy
Protease Inhibitors therapeutic use
Valsartan therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1533-4023
- Volume :
- 78
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of cardiovascular pharmacology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 34225338
- Full Text :
- https://doi.org/10.1097/FJC.0000000000001103